The price of Mesoblast Limited (NASDAQ:MESO) shares last traded on Wall Street rose 23.76% to $3.75.
Based on available information, 6 analysts follow Mesoblast Limited (NASDAQ:MESO). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $23.00 and a low of $2.50, we find $6.97. Given the previous closing price of $3.03, this indicates a potential upside of 130.03 percent. MESO stock price is now 13.79% away from the 50-day moving average and 20.24% away from the 200-day moving average. The market capitalization of the company currently stands at $546.56M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Among analysts, 0 rate the stock a hold while 5 rate it a buy. Brokers who have rated the stock have averaged $8.97 as their price target over the next twelve months.
On September 06, 2022, Piper Sandler recently initiated its ‘Overweight’ rating on the stock quoting a target price of $7, while ‘Maxim Group’ rates the stock as ‘Buy’.
There have been several recent changes in the stakes of large investors in MESO stock. A new stake in Mesoblast Limited shares was purchased by RONIT CAPITAL LLP during the first quarter worth $563,000. CITADEL ADVISORS LLC invested $516,000 in shares of MESO during the first quarter. In the first quarter, MILLENNIUM MANAGEMENT LLC acquired a new stake in Mesoblast Limited valued at approximately $443,000. JANE STREET GROUP, LLC acquired a new stake in MESO for approximately $236,000. OLD MISSION CAPITAL, LLC purchased a new stake in MESO valued at around $187,000 in the second quarter. In total, there are 48 active investors with 2.60% ownership of the company’s stock.
A candlestick chart of Mesoblast Limited (NASDAQ: MESO) showed a price of $3.3600 on Wednesday morning. During the past 12 months, Mesoblast Limited has had a low of $2.14 and a high of $4.94. As of last week, the company has a debt-to-equity ratio of 0.22, a current ratio of 1.40, and a quick ratio of 1.40. The fifty day moving average price for MESO is $3.3086 and a two-hundred day moving average price translates $3.1177 for the stock.
The latest earnings results from Mesoblast Limited (NASDAQ: MESO) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$0.12, beating analysts’ expectations of -$0.16 by 0.04. This compares to -$0.20 EPS in the same period last year. The company reported revenue of $2.13 million for the quarter, compared to $2.38 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -10.45 percent. For the current quarter, analysts expect MESO to generate $2.1M in revenue.
Mesoblast Limited(MESO) Company Profile
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
